July 14(Reuters) - Beijing Bohui Innovation Technology Co Ltd <300318.SZ> ::* Sees H1 FY 2017 net profit to increase by 20 percent to 40 percent, or to be 14.7 million yuan to 17.2 million yuan.* Says H1 FY 2016 net profit was 12.3 million yuan.* The reasons for the forecast are contribution from subsidiary and increased sales in inspection and testing business .
July 12 (Reuters) - Guangdong Hybribio Biotech Co Ltd <300639.SZ>:* Sees H1 FY 2017 net profit to increase by 8 percent to 18 percent, or to be 36.2 million yuan to 39.5 million yuan.* Says H1 FY 2016 net profit was 33.5 million yuan.* Says that improved business performance as main reason for the forecast.
July 5 (Reuters) - Nevro Corp : :Nevro announces preliminary unaudited second quarter 2017 revenue and business update.Sees Fy 2017 revenue $310 million to $320 million.Sees Q2 revenue $77.5 million to $78 million.Nevro Corp - company expects worldwide revenue for full year 2017 to be in range of $310.0 to $320.0 million..Nevro Corp- preliminary unaudited U.S. revenue for Q2 of 2017 is expected to be in range of $62.7 to $63.0 million.Nevro Corp - preliminary unaudited international revenue for Q2 of 2017 is expected to be in range of $14.8 to $15.0 million.Says additionally, company announced that michael enxing, vice president of sales, is no longer with company.Nevro Corp - company announced that preliminary unaudited Q2 worldwide revenue is expected to be in range of $77.5 to $78.0 million.
June 29 (Reuters) - Cardiovascular Systems Inc :Cardiovascular Systems - On June 27, 2017, Plaintiffs filed an amended complaint regarding Shoemaker V. Cardiovascular Systems case.Cardiovascular Systems- complaint makes allegations co made materially false, misleading statements,failed to disclose material adverse facts about business.Cardiovascular Systems - Plaintiffs seek unspecified monetary damages on behalf of alleged class, interest, attorney's fees and costs of litigation.Cardiovascular Systems Inc - Complaint relates to alleged kickbacks to health care providers - SEC Filing.
June 26 (Reuters) - Lattice Biologics Ltd -:Relocation of its processing facilities to Belgrade, Montana.Lattice Biologics - relocation occurred on june 24, and company has sufficient finished inventory to meet demand until processing resumes in montana.
June 13 (Reuters) - TAMBURI INVESTMENT PARTNERS SPA (TIP) ::TO LAUNCH SALE OF AMPLIFON S.P.A. <<>> SHARES BY ACCELERATED BOOKBUILDING DEDICATED TO QUALIFIED INVESTORS IN ITALY AND ABROAD.INTENDS TO SELL 3.5 MILLION ORDINARY SHARES OF AMPLIFON S.P.A., REPRESENTING 1.55% OF AMPLIFON’S SHARE CAPITAL AND REPRESENTING 1.06% OF THE VOTING RIGHTS.AMPLITER NV AT THE SAME TIME HAS LAUNCHED SALE OF 5.5 MILLION SHARES OF AMPLIFON REPRESENTING 2.43% OF THE SHARE CAPITAL AND 1.66% OF THE VOTING RIGHTS.ACCELERATED BOOKBUILD PROCEDURE TO BE CARRIED OUT BY MORGAN STANLEY AND UNICREDIT BANK AG, MILAN BRANCH (IN COOPERATION WITH KEPLER CHEUVREUX) AS JOINT BOOKRUNNERS.THE ACCELERATED BOOKBUILDING TRANSACTION IN THE CONTEXT OF A FURTHER INVESTMENT OF 50 MILLION EURO BY TIP IN AMPLITER SHARE CAPITAL.
May 12 (Reuters) - PRIM SA ::SAYS TO MERGE WITH ITS UNIT ENRAF NONIUS IBERICA S.A.U.
May 11 (Reuters) - Cytori Therapeutics Inc ::Cytori reports first quarter 2017 business and financial results.Q1 adjusted loss per share $0.26 excluding items.Q1 GAAP loss per share $0.33.Q1 revenue $1.6 million versus $2.9 million.Q1 revenue view $2.6 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S.Says expects full year 2017 operating cash burn to be higher than 2016.Cytori therapeutics inc - 2017 financial guidance reiterated.
May 11 (Reuters) - Volitionrx Ltd : :Volitionrx Limited announces first quarter 2017 financial results and business update.Q1 loss per share $0.13.Q1 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S.Volitionrx - cash, cash equivalents as of March 31, 2017 $18.5 million, compared to $21.7 million as of December 31, 2016 and $17.0 million as of March 31, 2016.